Scarica l'app Stockscreener
1.16
0.87%
0.01
Dopo l'orario di chiusura:
1.14
-0.02
-1.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.15
Aprire:
$1.11
Volume 24 ore:
797.65K
Relative Volume:
0.24
Capitalizzazione di mercato:
$151.34M
Reddito:
-
Utile/perdita netta:
$-97.17M
Rapporto P/E:
-1.5539
EPS:
-0.7465
Flusso di cassa netto:
$-85.97M
1 W Prestazione:
-7.94%
1M Prestazione:
+9.43%
6M Prestazione:
+20.42%
1 anno Prestazione:
+4.50%
Intervallo 1D:
$1.10
$1.16
Intervallo di 1 settimana:
$1.03
$1.28
Portata 52W:
$0.5062
$1.51
Immunic Inc Stock (IMUX) Company Profile
Nome
Immunic Inc
Settore
Industria
Telefono
(332) 255-9818
Indirizzo
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.16 | 151.34M | 0 | -97.17M | -85.97M | -0.7465 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Iniziato | Guggenheim | Buy |
| 2025-11-07 | Iniziato | Roth Capital | Buy |
| 2025-09-29 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-25 | Iniziato | William Blair | Outperform |
| 2024-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-27 | Iniziato | B. Riley Securities | Buy |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2021-04-15 | Iniziato | Aegis Capital | Buy |
| 2021-03-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-08-07 | Ripresa | ROTH Capital | Buy |
| 2020-07-20 | Iniziato | BMO Capital Markets | Outperform |
| 2020-06-05 | Iniziato | Wedbush | Outperform |
| 2020-05-11 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-25 | Iniziato | ROTH Capital | Buy |
| 2019-07-11 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Immunic Inc Borsa (IMUX) Ultime notizie
If You Invested $1,000 in Immunic Inc (IMUX) - Stock Titan
IMUX SEC FilingsImmunic Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Immunic to offer up to 458.2 million shares of common stock registered for resale by selling stockholdersSEC filing - MarketScreener
Immunic To Offer Up To 458.2 Million Shares Of Common Stock Registered For Resale By Selling StockholdersSEC Filing - TradingView
According to the latest filing with the U.S. Securities and Exchange Commission (SEC), the biopharmaceutical company Immunic, Inc. has initiated an equity resale program. - Bitget
Immunic (NASDAQ: IMUX) registers 458.2M resale shares after $200M private placement - Stock Titan
Immunic Regains Nasdaq Compliance, Stabilizing Listing Status - The Globe and Mail
Immunic regains Nasdaq minimum bid price compliance By Investing.com - Investing.com South Africa
Immunic, Inc. (IMUX) stock price, news, quote and history - Yahoo Finance UK
IMUX Forecast, Price Target & Analyst Ratings | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement - Sahm
Immunic, Inc. (IMUX) latest stock news and headlines - sg.finance.yahoo.com
Immunic Regains Nasdaq Compliance as IMUX Stock Maintains Minimum Bid Price Requirement - Minichart
Immunic regains Nasdaq minimum bid price compliance - Investing.com
Immunic Regains Nasdaq Minimum Bid Price Compliance After 20 Consecutive Business Days - TradingView
[8-K] IMMUNIC, INC. Reports Material Event - Stock Titan
Immunic AG / US4525EP1011 - AD HOC NEWS
Immunic appoints Jon Congleton to board of directors By Investing.com - Investing.com Australia
Immunic (IMUX) director Jon Congleton files initial Form 3 - Stock Titan
Immunic Appoints Biopharma Leader Jon Congleton to Board, Advancing MS Therapy Toward Phase 3 Pivotal Readouts - Minichart
Small cap wrap: BioHarvest Sciences, American Resources, First Phosphate, Immunic... - Proactive financial news
Immunic Adds Veteran Biopharma Leader to Board - TipRanks
Immunic appoints biopharmaceutical executive Jon Congleton to board - Yahoo! Finance Canada
Immunic Appoints Jon Congleton To Board - citybiz
Immunic appoints Jon Congleton to board of directors - Investing.com
Biopharmaceutical company Immunic, Inc. recently announced the appointment of experienced industry executive Jon Congleton to its board of directors. - Bitget
Veteran biotech leader Jon Congleton joins Immunic (NASDAQ: IMUX) board - Stock Titan
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton - ChartMill
Smart Money: Is Immunic Inc stock a good dividend stock2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
Growth Review: Is Immunic Inc undervalued by DCF analysisMarket Movement Recap & Fast Gaining Stock Reports - baoquankhu1.vn
Pharma News: Whats next for Immunic Inc stock2026 Action & Fast Gaining Stock Reports - baoquankhu1.vn
Immunic Inc Stock Warning Signs - GuruFocus
Guggenheim initiates coverage of Immunic (IMUX) with buy recommendation - MSN
Immunic stock jumps after Guggenheim initiates with Buy By Investing.com - ca.investing.com
Immunic (IMUX) Gains on Guggenheim's Buy Rating and Promising Dr - GuruFocus
Immunic stock jumps after Guggenheim initiates with Buy - Investing.com UK
Immunic stock gains new Buy at Guggenheim (IMUX:NASDAQ) - Seeking Alpha
Immunic (NASDAQ:IMUX) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
IMUX: Guggenheim Initiates Coverage with a Buy Rating and $7 Pri - gurufocus.com
Guggenheim Initiates Coverage on Immunic With Buy Rating, $7 Price Target - marketscreener.com
Immunic stock initiated at Buy by Guggenheim on MS therapy potential By Investing.com - za.investing.com
Immunic stock initiated at Buy by Guggenheim on MS therapy potential - Investing.com South Africa
Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Tangible book value per share of Immunic, Inc. – FWB:10VA - TradingView
Bull Bear: Does Immunic Inc meet Warren Buffetts criteria2026 Sector Moves & Expert-Curated Trade Recommendations - baoquankhu1.vn
US Stocks Recap: Will Immunic Inc stock recover after earningsFed Meeting & Weekly Return Optimization Alerts - baoquankhu1.vn
Immunic, Inc. (IMUX) announces European patent grant for vidofludimus calcium - MSN
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium - Insider Monkey
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next - MarketBeat
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug By Investing.com - Investing.com Canada
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug - Investing.com
Immunic Inc Azioni (IMUX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):